Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Cephalon agrees to acquisition by Teva

Cephalon agrees to acquisition by Teva

4th May 2011

Cephalon has approved an acquisition deal by fellow pharmaceutical company Teva that has been valued at around $6.8 billion (4.12 billion pounds).

The offer trumps the $5.7 billion takeover bid launched by Valeant Pharmaceuticals earlier this year and has been deemed by Cephalon's board of directors to offer value to its shareholders.

When the planned deal closes in the third quarter of 2011, it will create a combined organisation with a branded portfolio worth around $7 billion in annual sales, as well as a pipeline including more than 30 late-stage investigational compounds.

The transaction is expected to create a new leader in specialty pharmaceuticals, with a strong presence in fields such as central nervous system and respiratory conditions, as well as oncology and pain management.

Generics specialist Teva also believes the buyout will help it to expand and diversify its branded and specialty pharmaceuticals business interests.

Kevin Buchi, chief executive officer of Cephalon, said: "By joining forces with Teva, we will benefit from their scale, worldwide reach and operational excellence, allowing us to further pursue our shared goals of delivering new innovative therapies."ADNFCR-8000103-ID-800518333-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.